Healthcare

For a disease that has spent decades at the margins of pharmaceuticalInvestment, hereditary angioedema has never lacked for urgency. Its sufferers endure episodes of sudden, severe swelling — in the face, limbs, gut and, most dangerously, the throat — triggered by stress, infection or, …

Eli Lilly (NYSE:LLY) is one of the most strategically transformed large-cap pharmaceutical companies of the modern era. Over the past several years, it has gone from a diversified pharma with steady but unspectacular growth into the dominant Western operator in the GLP-1 metabolic franchise …

Edwards Lifesciences (NYSE:EW) opened fiscal 2026 with a quarter that reinforced the investment case for its concentrated structural heart strategy. Total revenue of $1.65 billion grew 12.7% year-over-year, clearing analyst expectations. Adjusted EPS of $0.78 beat the $0.73 forecast, while GAAP EPS came in …

A Beat That Failed to Reassure Markets

HeartBeam has announced a $10 million public offering at a strategically important stage in its corporate development. Unlike many small-cap financings that are purely defensive in nature, this transaction carries an additional signaling effect due to participation from the company’s first commercial customer and …

Kazia Therapeutics has re-entered investor discussions following a favorable analyst initiation that assigned a Buy rating and a $25 price target. The optimism is centered on paxalisib, the company’s lead oncology candidate, and expectations for multiple upcoming catalysts over the next two years.

Aligos Therapeutics has delivered a meaningful operational and regulatory update for its chronic hepatitis B virus program. The company announced that the independent Data Safety Monitoring Board recommended continuation of the Phase 2 B-SUPREME study, while also endorsing expansion of a key patient cohort.